International Journal of Hematology and Oncology 2022, Vol 32, Num 2 Page(s): 179-184
Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period

Filiz VURAL1, Emin KARACA2, Nur SOYER1, Cumhur GUNDUZ3, Fahri SAHIN1, Buket KOSOVA3, Guray SAYDAM1, Seckin CAGIRGAN1, Murat TOMBULOGLU1, Ferda OZKINAY2, Ozgur COGULU2

1Ege University, Faculty of Medicine, Department of Hematology, Izmir, TURKEY
2Ege University, Faculty of Medicine, Department of Medical Genetics, Izmir, TURKEY
3Ege University, Faculty of Medicine, Department of Medical Biology, Izmir, TURKEY

Keywords: hTERT, CD38, ZAP70, Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. Recently CD38, ZAP70 and hTERT activity have been studied for the evaluation of the prognosis of CLL besides clinical staging and lymphocyte doubling time. There are inconsistent results regarding these markers for the evaluation of the prognosis in CLL patients. In this study CD38, ZAP70 and hTERT values in CLL patients were measured to make comparisons between each other and known prognostic factors. Thirty CLL patients who were included in the study were followed up for 5 years after the initial diagnosis. The mean hTERT value in CLL and control cases were 1.00±1.31 and 3.89±3.58, respectively (p< 0.05). The mean CD38 and ZAP70 were 6.20±7.60 and 5.51±5.67, respectively. No significant association was detected between CD38, ZAP70 and hTERT activity. There was no correlation between those parameters and known prognostic parameters such as Rai staging, peripheral lymphocyte levels, age, and sex of the patients, beta-2 microglobulin and reply to treatment in CLL. The overall five-year survival rate in CLL patients is 96.7%. The overall five-year survival rate in CLL patients is 96.7%. In conclusion, further studies including larger series of patients with longer follow-up periods are recommended.